文献速递血栓与止血

凝血因子VIIa释放的细胞外囊泡减轻关节出血诱导的血友病性关节病

Factor VIIa-released extracellular vesicles attenuate joint bleed-induced hemophilic arthropathy.
PubMed 文献 · Blood · 2026-01-01

本研究在血友病(F8-/-)小鼠中通过针刺损伤诱导关节出血,比较生理盐水、对照内皮细胞来源细胞外囊泡(eEVs)与凝血因子VIIa(FVIIa)释放的eEVs对血友病性关节病(HA)的影响。结果显示对照eEVs对HA发展无显著影响,而FVIIa释放的eEVs显著减轻关节出血诱导HA的全部病理特征;该保护作用依赖miR10a,且miR10a对止血无影响。

要点

  • FVIIa释放的eEVs显著减轻关节出血诱导HA的全部病理特征。
  • 对照eEVs对HA发展无显著影响。
  • miR10a抑制剂消除保护作用,miR10a模拟物赋予对照eEVs保护作用。

核心结论

  • 含miR10a的细胞外囊泡能有效抑制滑膜炎症,在治疗HA方面具有巨大治疗价值。

研究设计与样本

  • 研究在血友病(F8-/-)小鼠中通过针刺损伤诱导关节出血。
  • 损伤小鼠分别接受生理盐水、对照eEVs或FVIIa释放的eEVs治疗,通过膝关节大体检查及组织学、免疫组化分析评估变化。

主要发现

  • 对照eEVs治疗对HA发展无显著影响,而FVIIa释放的eEVs显著减轻关节出血诱导HA的全部病理特征。
  • 将miR10a抑制剂掺入FVIIa释放的eEVs消除了其对HA的保护作用。
  • 将miR10a模拟物加载到对照eEVs中赋予了保护作用。
  • 给予含miR10a的FVIIa释放eEVs或加载miR10a模拟物的对照eEVs可消除滑膜中关节出血诱导的白细胞介素-6产生。
  • eEVs中的miR10a对止血无影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Repeated bleeding into joints in hemophilia leads to chronic inflammation that plays a central role in the pathogenesis of hemophilic arthropathy (HA). Our recent studies revealed that factor VIIa (FVIIa) treatment releases extracellular vesicles from endothelial cells (eEVs) and FVIIa-released eEVs exhibit anti-inflammatory and barrier-protective functions. The present study was undertaken to investigate the effect of FVIIa-released eEVs on HA and the mechanism of their protective effect. Joint bleeding in hemophilia (F8-/-) mice was induced by a needle puncture injury. Injured mice were treated with saline, control eEVs, or FVIIa-released eEVs, and the changes in the knee joints were analyzed by gross examination of knees as well as histological and immunohistochemical analysis. Joint tissues were examined for evidence of synovial hyperplasia, macrophage infiltration, neoangiogenesis, cartilage degeneration, and chondrocyte apoptosis. The data showed that treatment of mice with control eEVs had no significant effect on the development of HA, whereas treatment with FVIIa-released eEVs markedly reduced all pathological features of joint bleed-induced HA. Incorporation of microRNA10a (miR10a) inhibitor into FVIIa-released eEVs abrogated the protective effect of FVIIa-released eEVs on HA. More importantly, loading miR10a mimic into control eEVs conferred a protective effect. Administration of miR10a-containing FVIIa-released eEVs or control eEVs loaded with miR10a mimic was found to abrogate joint bleed-induced interleukin-6 production in the synovium. miR10a in eEVs had no effect on hemostasis. Cumulatively, our data indicate that EVs containing miR10a that effectively suppress synovial inflammation would have immense therapeutic value in treating HA.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kavadipula P, Keshava S, Das K, et al. Factor VIIa-released extracellular vesicles attenuate joint bleed-induced hemophilic arthropathy. Blood. 2026. PMID: 40834879. doi:10.1182/blood.2024027143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。